Why the study?
Is ezetimibe added to statin therapy cost-effective compared to statin monotherapy in patients with a history of CHD/stroke and LDL-C ≥70 mg/dL?
Population
Patients aged 35-74 years with a history of coronary heart disease and/or stroke, and with low-density…
Comparison
Ezetimibe 10 mg added to statin therapy vs Statin monotherapy
Follow-up
lifetime horizon
Authors
Loading...
Supports generic ezetimibe add-on as potentially cost-effective from US payer view; leaves open need for updated real-world validation.
Is ezetimibe added to statin therapy cost-effective compared to statin monotherapy in patients with a history of CHD/stroke and LDL-C ≥70 mg/dL?
Adding ezetimibe to statin therapy is highly cost-effective for secondary prevention of CHD and stroke in the US, particularly when accounting for generic pricing.
Davies et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: